Glycomet-GP 0.5 Tablet (Metformin/Glimepiride)

Product Overview

Glycomet‑GP 0.5 Tablet (Metformin/Glimepiride) is a prescription oral antihyperglycemic agent indicated for the management of type 2 diabetes mellitus. Manufactured by USV Pvt Ltd, each strip contains ten tablets, each delivering a fixed dose of 500 mg metformin combined with 0.5 mg glimepiride. The product is packaged in strengths of 500 mg/0.5 mg per tablet and is available in pack sizes of 60, 120, or 240 tablets, providing flexibility for patients and clinicians seeking long‑term glycemic control. This medication belongs to the biguanide and sulfonylurea classes, offering complementary mechanisms that improve insulin sensitivity and stimulate insulin secretion from pancreatic β‑cells. The product is shipped in blister packs that protect each tablet from moisture and light, ensuring stability throughout the 6‑to‑15‑day delivery window offered by authorized online pharmacies. Patients can select from 60, 120, or 240‑tablet packs based on their treatment duration, allowing cost‑effective bulk purchasing while maintaining consistent potency.

What is Glycomet‑GP 0.5 Tablet (Metformin/Glimepiride)

Glycomet‑GP 0.5 Tablet combines two active pharmaceutical ingredients in a single film‑coated tablet. Metformin, a biguanide, reduces hepatic glucose production and enhances peripheral insulin sensitivity. Glimepiride, a second‑generation sulfonylurea, binds to the K‑ATP channels on pancreatic β‑cells, prompting increased insulin release. The fixed‑dose formulation simplifies dosing regimens and improves adherence, especially for patients who previously required separate tablets of each component. The tablet’s strength of 500 mg metformin with 0.5 mg glimepiride is calibrated to provide an optimal balance between glycemic reduction and risk of hypoglycemia when used as directed. Because the two active agents are combined in a single tablet, the formulation reduces pill burden, minimizes inter‑tablet variability, and simplifies routine monitoring, which collectively contribute to better adherence and improved long‑term glycemic outcomes.

Uses and Benefits

Glycomet‑GP 0.5 Tablet is primarily prescribed for patients with type 2 diabetes who have not achieved adequate glycemic control with metformin alone. The addition of glimepiride provides a rapid post‑prandial insulin response, reducing blood glucose spikes after meals. Clinical studies have demonstrated that combination therapy can lower HbA1c by up to 1.5 % compared with metformin monotherapy, while also supporting modest weight stability. In addition to glycemic control, epidemiologic data suggest that the combination may confer modest cardiovascular benefits, including reduction in triglyceride levels and improvement in high‑density lipoprotein cholesterol, further supporting its role in comprehensive diabetes management. For many patients, the dual‑action approach reduces the need for multiple daily injections or frequent dose adjustments, thereby improving quality of life. Moreover, the fixed‑dose format decreases pill burden, which is associated with higher persistence in long‑term treatment regimens.

How It Works

The therapeutic effect of Glycomet‑GP 0.5 Tablet emerges from the synergistic action of its two constituents. Metformin activates AMP‑activated protein kinase (AMPK) in liver and muscle cells, leading to decreased gluconeogenesis and increased peripheral glucose uptake. This results in lower fasting plasma glucose concentrations. Glimepiride, by closing ATP‑sensitive potassium channels on β‑cells, triggers calcium influx and exocytosis of insulin‑containing vesicles, producing a dose‑dependent increase in circulating insulin. Activation of AMPK not only suppresses hepatic glucose output but also enhances fatty acid oxidation in skeletal muscle, contributing to modest weight loss and improved lipid profile. This dual metabolic effect distinguishes metformin from other glucose‑lowering agents and underscores the complementary mechanism of action when paired with glimepiride. The combined effect yields a dual reduction in both basal and post‑prandial hyperglycemia, providing comprehensive glycemic control that is reflected in improved HbA1c values and reduced glycemic variability.

Dosage Guidelines

The recommended starting dose of Glycomet‑GP 0.5 Tablet is one tablet taken orally once daily with the first main meal of the day. If additional glycemic control is required, the dose may be titrated upward by 0.5 tablet (i.e., 250 mg metformin/0.25 mg glimepiride) at intervals of 1–2 weeks, up to a maximum of two tablets daily, provided that renal function remains stable and no signs of hypoglycemia occur. Patients with impaired renal function should undergo dose reduction or alternative therapy, as metformin accumulation can precipitate lactic acidosis. Titration should be performed under the supervision of a qualified healthcare professional, with periodic assessment of renal function using estimated glomerular filtration rate (eGFR). If eGFR falls below 45 mL/min/1.73 m², the dose should be reduced or discontinued to prevent accumulation of metformin and its metabolites.

Side Effects

Like all antidiabetic agents, Glycomet‑GP 0.5 Tablet may be associated with adverse events. The most commonly reported side effects include gastrointestinal discomfort such as nausea, diarrhea, abdominal cramping, and a metallic taste. Occasionally, patients experience headache, dizziness, or mild edema. Rare but serious complications comprise lactic acidosis, severe hypoglycemia, and cutaneous reactions such as rash or pruritus. Very rare adverse events have included liver enzyme elevations, pancreatitis, and severe skin reactions such as Stevens‑Johnson syndrome. Although these occurrences are infrequent, awareness of their symptoms is essential for early detection and prompt medical intervention.

Warnings and Precautions

Glycomet‑GP 0.5 Tablet is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, or known hypersensitivity to metformin, glimepiride, or any component of the formulation. Caution is advised in elderly patients, those with hepatic disease, or individuals undergoing radiographic contrast procedures, as these conditions may increase the risk of lactic acidosis. According to the National Institutes of Health (NIH) NIH, the incidence of lactic acidosis is higher in individuals with compromised renal function. Concomitant use of certain medications—such as certain antipsychotics, corticosteroids, or diuretics—can potentiate hyperglycemia and may necessitate dose adjustments. Additionally, patients should avoid excessive alcohol intake, as alcohol can exacerbate the risk of lactic acidosis and impair glycemic control. Pregnant or breastfeeding women should only use this medication under the supervision of a qualified healthcare professional. The U.S. Food and Drug Administration (FDA) provides detailed prescribing information at FDA.

FAQs

What should I do if I miss a dose of Glycomet‑GP 0.5 Tablet?

If a dose is missed, take it as soon as you remember, provided it is within 6 hours of the scheduled time. If it is later than that, skip the missed dose and resume your regular dosing schedule. Do not double the dose to catch up.

Can Glycomet‑GP 0.5 Tablet be taken with food?

Yes, the tablet should be taken with the first main meal of the day to reduce gastrointestinal side effects and to enhance absorption of metformin. Taking it on an empty stomach may increase the risk of nausea.

Is Glycomet‑GP 0.5 Tablet safe during pregnancy?

Glycomet‑GP 0.5 Tablet is generally not recommended during pregnancy because glimepiride crosses the placenta and may affect fetal development. Pregnant women should consult their obstetrician for alternative antidiabetic therapies that are considered safe.

What storage conditions are required for Glycomet‑GP 0.5 Tablet?

Store the tablets at room temperature, away from moisture and heat. Keep the strip sealed until use and retain it in its original packaging to protect from light. Do not refrigerate or freeze the medication.

Are there any drug interactions I should be aware of?

Yes, several medications can interact with Glycomet‑GP 0.5 Tablet, including certain beta‑blockers, certain antibiotics such as trimethoprim‑sulfamethoxazole, and high‑dose corticosteroids, which may affect blood glucose levels. Always inform your healthcare provider of all prescription, over‑the‑counter, and herbal products you are using.

Related Products

• Erytop Gel (Clindamycin)
• Okamet 500 Mg (Metformin)
• Angispan TR (Nitroglycerin/Glyceryl Trinitrate)
• Angispan TR 2.5 mg (Nitroglycerin/Glyceryl Trinitrate)
• Angispan TR 6.5 mg (Nitroglycerin/Glyceryl Trinitrate)
• Glimepiride 2 mg (Generic)
• Glimepiride 1 mg (Generic)
• Glycomet-GP 0.5 Forte (Metformin/Glimepiride)
• Forxiga 5mg (Dapagliflozin)
• Glycomet-GP 1 Tablet (Metformin/Glimepiride)
• Amaryl M 1mg (Metformin/Glimepiride)
• Glycomet-GP 2 Forte (Metformin/Glimepiride)